Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

STOP PRESS: Sygnature Discovery named as Finalist in OBN Awards 2017 Best CRO category

Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, is pleased to announce that it is a finalist in the OBN Awards 2017 Best Contract Research Organisation category.

The OBN Awards 2017, now in their 9th year, celebrate innovation and outstanding achievement across the UK Life Sciences industry. Categories are broad ranging and include Biotech, Medtech, Synthetic Biology, Digital Healthcare and Investment.

This year OBN is launching a brand-new category, Best Contract Research Organisation which looks to recognise the critical support services provided by CROs across the pharmaceutical, biotech and medtech industries.

The Awards dinner will take place on Thursday 5th October 2017 at Oxford Town Hall.  For more information on the OBN Awards 2017, go to: http://www.obn-awards.com/

 

Latest News

View All

Sygnature Discovery wins Outstanding Achievement Award

RenaSci’s Sharon Cheetham awarded BPS Fellowship

Sygnature Discovery invests in high-throughput screening capability

Sygnature Discovery moves US base to Kendall…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.